5-氰基-3-甲基-1H-吲哚-2-羧酸 | 169463-46-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-氰基-3-甲基-1H-吲哚-2-羧酸
• 英文名称: 3-methyl-5-cyanoindole-2-carboxylic acid
• 英文别名: 5-cyano-3-methyl-1H-indole-2-carboxylic Acid
• CAS: 169463-46-1
• 化学式: C₁₁H₈N₂O₂
• 分子量: 200.197
• InChiKey: XDPWTCVJQGONFN-UHFFFAOYSA-N

物化性质

• 沸点：
  493.7±40.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  76.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氰基-3-甲基-1H-吲哚-2-羧酸 在 吡啶 、 4-二甲氨基吡啶 、 TEA 、 硫化氢 、 ammonium acetate 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 、 碘甲烷 作用下， 生成 methyl 7-[(5-carbamimidoyl-3-methyl-1H-indole-2-carbonyl)amino]heptanoate
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k
• 作为产物：
  描述：

  3-甲基-4-硝基苯甲腈 在 lithium hydroxide 、 sodium 、 sodium hydride 、 溶剂黄146 、 锌 作用下， 以 乙醇 为溶剂， 生成 5-氰基-3-甲基-1H-吲哚-2-羧酸
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k

文献信息

• [EN] PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RECEPTEURS ACTIVES PAR LES PROLIFERATEURS DE PEROXYSOMES
  申请人：LILLY CO ELI

  公开号：WO2005054176A1

  公开（公告）日：2005-06-16

  The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种式（I）的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，可用于治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉粥样硬化以及其他与X综合征和心血管疾病相关的疾病。
• Peroxisome proliferator activated receptor modulators
  申请人：Canada Jane Emily

  公开号：US20070082907A1

  公开（公告）日：2007-04-12

  The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种式（I）的化合物，或其药学上可接受的盐、溶剂水合物或立体异构体，其可用于治疗或预防由过氧化物酶体增殖激活受体（PPAR）介导的疾病，例如X综合征、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉硬化和其他与X综合征和心血管疾病相关的疾病。
• 5,6-Bicyclic glycoprotein IIb IIIa antagonists useful in inhibition of platelet aggregation
  申请人：ELI LILLY AND COMPANY

  公开号：EP0655439A2

  公开（公告）日：1995-05-31

  This invention relates to 5,6 fused ring bicyclic compounds inclusive of indoles, benzofurans, and benzothiophenes, and corresponding to the formula (I) substituted with both basic (B) and acidic (A) functionality, which are useful in inhibition of platelet aggregation.

  本发明涉及包括吲哚、苯并呋喃和苯并噻吩在内的5,6融合环双环化合物，并对应于式(I) 被碱性（B）和酸性（A）官能团取代，可用于抑制血小板聚集。
• PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1697304B1

  公开（公告）日：2008-02-20
• Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists
  作者：Daniel J. Sall、Ann E. Arfsten、Jolie A. Bastian、Michael L. Denney、Cathy S. Harms、Jefferson R. McCowan、John M. Morin,、Jack W. Rose、Robert M. Scarborough、Mark S. Smyth、Suzane L. Um、Barbara G. Utterback、Robert T. Vasileff、James H. Wikel、Virginia L. Wyss、Joseph A. Jakubowski

  DOI：10.1021/jm970020k

  日期：1997.8.1

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.